Pharmacognosy intro
Saw Palmetto's primary active fraction is the liposterolic extract containing fatty acids, lauric acid (25-30%), oleic acid (25-35%), myristic acid (10-15%), palmitic acid (8-10%), linoleic acid (3-5%), along with phytosterols (β-sitosterol, campesterol, stigmasterol, cycloartenol), flavonoids (rutin, isoquercitrin, kaempferol), and polysaccharides. The PRIMARY mechanism is 5-alpha-reductase inhibition: fatty acids (particularly lauric and oleic acid) inhibit both Type I and Type II 5-alpha-reductase enzymes, blocking conversion of testosterone to dihydrotestosterone (DHT). This is the SAME mechanism as finasteride but non-selective (hitting both isoenzymes) with fewer sexual side effects. Additional mechanisms include competitive inhibition of DHT binding to androgen receptors in prostate tissue, inhibition of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways reducing prostaglandin and leukotriene production, and induction of apoptosis in prostate epithelial cells via caspase-3 activation. Critically, unlike finasteride, saw palmetto does NOT lower serum PSA, clinically important for prostate cancer screening.